FIELD: medicine, obstetrics. SUBSTANCE: method deals with periodic blood testing, that is: spectral- fluorescent assay of an extract of porphyrin fraction of venous blood erythrocytes. Moreover, one should detect the concentration of copro- and protoporphyrins and at the ratio value of protoporphyrins concentration to coproporphyrins concentration being under 10 gestosis is diagnosed. EFFECT: increased information value and increased number of methods for early diagnostics of gestosis. 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DIFFERENTIATED DETECTION OF GESTOSIS SERIOUSNESS DEGREE IN PREGNANT WOMEN | 2000 |
|
RU2181202C1 |
| METHOD OF PREDICTING THE DEVELOPMENT OF HYPERTENSIVE DISORDERS DURING PREGNANCY IN THE MIDDLE RISK GROUP AMONG THE WOMEN WHO UNDERWENT COMBINED SCREENING OF THE 1ST TRIMESTER | 2023 |
|
RU2803010C1 |
| DIAGNOSTIC TECHNIQUE FOR SEVERE GESTOSIS | 2011 |
|
RU2476880C1 |
| METHOD FOR PREDICTION OF SEVERE PREECLAMPSIA | 2020 |
|
RU2739694C1 |
| METHOD OF DIAGNOSING INCOMPLETE SPONTANEOUS ABORTION | 2022 |
|
RU2796877C1 |
| METHOD FOR PREDICTING THE DEVELOPMENT OF GESTOSIS | 2005 |
|
RU2295133C2 |
| METHOD FOR TREATING PREGNANT WOMEN WITH PREECLAMPSIA OF MODERATE SEVERITY | 2017 |
|
RU2657768C1 |
| PREDICTION OF PLACENTAL PREECLAMPSIA ACCORDING TO PLACENTOMETRY AT GESTATION 19-21 WEEKS IN LOW-RISK PATIENTS | 2021 |
|
RU2771762C1 |
| METHOD FOR PREDICTING EARLY PREECLAMPSIA ACCORDING TO THE LEVEL OF PROCOAGULANT ACTIVITY OF TISSUE FACTOR IN BLOOD PLASMA AT 19-21 WEEKS OF GESTATION IN PATIENTS OF THE LOW-RISK GROUP | 2022 |
|
RU2795083C1 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPING PREECLAMPSIA | 2023 |
|
RU2817206C1 |
